Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
VERAXA Biotech AG (NASDAQ: VRXA) has generated new in vitro proof-of-concept data validating its novel BiTAC-ADC technology platform.
-
The business combination of VERAXA Biotech and Voyager Acquisition Corp. was closed successfully and NASDAQ trading of $VRXA commences on June 11, 2026.
-
VERAXA Biotech AG has strengthened its financial position to position to support the closing of its business combination with Voyager Acquisition Corp.
-
VERAXA shareholders approve merger & issuance of new shares to Voyager. Both resolutions are prerequisites for the closing of the business combination.
-
ZURICH, SWITZERLAND, and MARTINSRIED/MUNICH, GERMANY – September 30, 2025 -- VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager...
-
ZURICH, SWITZERLAND, July 17, 2025 -- VERAXA Biotech AG (“VERAXA” or the "Company"), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted...
-
ZURICH, SWITZERLAND, May 29, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp....
-
VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH, “Voyager”), announced today the...
-
ZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG (“VERAXA”), an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp....
-
VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE")...